Search | Clinical Trials Finder

Conditions: Ichthyosis
Interventions: TMB-001, Matching Vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 6 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 18
States / cities: Phoenix, Arizona • Palo Alto, California • Centennial, Colorado + 15 more

Conditions: Alopecia Areata
Interventions: LEO 124249, Vehicle; Drug · Other
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Evanston, Illinois • New York, New York

Conditions: Congenital Ichthyosis
Interventions: Isotretinoin, Vehicle; Drug · Other
Lead sponsor: LEO Pharma; Industry
Eligibility: 9 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Phoenix, Arizona • Palo Alto, California • New Haven, Connecticut + 5 more

Conditions: Atopic Dermatitis, Plaque Psoriasis
Interventions: PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06%; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 23
States / cities: Encinitas, California • Los Angeles, California • Cape Coral, Florida + 17 more

Conditions: Dermatitis, Atopic
Interventions: AN2728 Topical Ointment, 2%, Matching vehicle control; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years and older
Enrollment: 764 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Henrico, Virginia

Conditions: Allergic Conjunctivitis
Interventions: hydrocortisone ophthalmic ointment 0.5%, placebo; Drug
Lead sponsor: Koffler Vision Group; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Psoriasis
Interventions: Vehicle (Placebo) applied BID, QRX-101 75 mcg/g ointment applied QD, QRX-101 75 mcg/g ointment applied BID; Drug
Lead sponsor: QuatRx Pharmaceuticals Company; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 12
States / cities: Hot Springs, Arkansas • Santa Rosa, California • Overland Park, Kansas + 9 more

Conditions: Dry Eye Disease
Interventions: AZR-MD-001, Vehicle; Drug · Other
Lead sponsor: Azura Ophthalmics; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 16
States / cities: Chandler, Arizona • Glendale, California • Newport Beach, California + 13 more

Conditions: Atopic Dermatitis
Interventions: Difamilast, Placebo; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more

Conditions: Atopic Dermatitis
Interventions: CD2027 Ointment 3 mcg/g, twice daily, Vehicle Ointment, twice daily; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 14
States / cities: Hot Springs, Arkansas • San Diego, California • Denver, Colorado + 10 more

Conditions: Plaque Psoriasis
Interventions: calcitriol ointment, placebo comparator; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 2 Years to 12 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 12
States / cities: Beverly Hills, California • Sacramento, California • Louisville, Kentucky + 9 more

Conditions: Sexual Pain Disorders, Postmenopausal Symptoms, Vulvovaginal Atrophy, Female Sexual Dysfunction, Dyspareunia, Vulvodynia, Vestibulodynia, Arousal Disorders, Sexual, Genito-Pelvic Pain/Penetration Disorder, Female Sexual Arousal Disorder
Interventions: 5% sinecatechins ointment, Placebo, 10% sinecatechins ointment; Drug
Lead sponsor: GTO Pharmaceutical, LLC; Other
Eligibility: 20 Years to 70 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: New York, New York • Nyack, New York

Conditions: Pruritus, Psoriasis
Interventions: SNA-120, Placebo, Calcipotriene; Drug
Lead sponsor: Sienna Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 17
States / cities: Anniston, Alabama • Mobile, Alabama • Fountain Valley, California + 14 more

Conditions: Diabetic Foot Ulcers
Interventions: Santyl, White Petrolatum; Drug · Other
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: Sylmar, California • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Atopic Dermatitis
Interventions: Crisaborole 2%, Vehicle treatment, Accelerometry device for children, Accelerometry device for adult caregivers; Drug · Device
Lead sponsor: Boston University; Other
Eligibility: 3 Months to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
Interventions: BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, BPR277; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: New Haven, Connecticut • St Louis, Missouri • Fargo, North Dakota

Conditions: Pruritus
Interventions: Ketamine Hydrochloride, Amitriptyline Hydrochloride, Lidocaine Hydrochloride, Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride, Lipoderm Cream; Drug · Combination Product
Lead sponsor: Gil Yosipovitch; Other
Eligibility: 18 Years to 50 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Eczema Atopic Dermatitis, Eczema, Atopic Dermatitis
Interventions: GX-03, Vehicle; Combination Product · Other
Lead sponsor: Turn Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Irving, Texas

Conditions: Epidermolysis Bullosa Simplex
Interventions: diacerein 1% ointment, A placebo ointment; Drug
Lead sponsor: Castle Creek Pharmaceuticals, LLC; Industry
Eligibility: 4 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 12
States / cities: Phoenix, Arizona • Palo Alto, California • Aurora, Colorado + 8 more

Conditions: Atopic Dermatitis, Plaque Psoriasis
Interventions: PF-07038124 ointment, Vehicle ointment; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 15
States / cities: Fountain Valley, California • Cape Coral, Florida • Clearwater, Florida + 12 more

Conditions: Atopic Dermatitis
Interventions: RVT-501 0.2% ointment, RVT-501 0.5% ointment, Vehicle ointment; Drug · Other
Lead sponsor: Dermavant Sciences GmbH; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 16
States / cities: Fremont, California • Los Angeles, California • San Diego, California + 10 more

Conditions: Pruritus, Psoriasis Vulgaris
Interventions: SNA-120, Vehicle; Drug
Lead sponsor: Sienna Biopharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 38
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 35 more

Conditions: Acne Rosacea
Interventions: ACCU-D1, Vehicle; Drug
Lead sponsor: Accuitis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Louisville, Kentucky • Austin, Texas

Conditions: Atopic Dermatitis (AD)
Interventions: CGB-500 with 0.5% tofacitinib, CGB-500 Ointment with 1% tofacitinib, Vehicle (placebo); Drug
Lead sponsor: CAGE Bio Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 16
States / cities: Fremont, California • Manhattan Beach, California • San Diego, California + 13 more

Search by objective public record fields.

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

LEO 124249 Ointment in the Treatment of Alopecia Areata

A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis

Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis

Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

Plaque Psoriasis Study in Pediatric Subjects

Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

A Study to Look at the Effects of Four Weeks of Treatment on the Healing of Diabetic Foot Ulcers

Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis

Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis

Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris

Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea

Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis